Deciphering the molecular heterogeneity of HER2-positive breast cancer: the critical interplay of hormone receptor status and transcriptomic landscapes.

doi:10.1007/s00726-026-03534-0

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Deciphering the molecular heterogeneity of HER2-positive breast cancer: the critical interplay of hormone receptor status and transcriptomic landscapes.

Amino acids - 16 Jun 2026

Sengul Ilker, Sengul Demet, Akalin Cagri

Abstract excerpt

The clinical management of HER2-positive breast cancer is undergoing a paradigm shift, recognizing that hormone receptor (HR) co-expression defines a fundamental biological dichotomy rather than a minor clinical variation. This perspective evaluates the profound heterogeneity within the HER2-positive subclass, where HR status acts as a master regulator of genomic landscapes and patient outcomes. Evidence from...

Read the complete abstract on PubMed

Topics

Humans
Breast Neoplasms
Erb-b2 Receptor Tyrosine Kinases
Female
Transcriptome
Receptors, Estrogen

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Gene Expression Regulation, Neoplastic

Receptors, Progesterone

Tumor Microenvironment

Biomarkers, Tumor

Class I Phosphatidylinositol 3-Kinases

Tumor Suppressor Protein p53

Mutation

Glucuronosyltransferase

Source

Open in PubMed Open full text

Identifiers

PMID: 42301336
DOI: 10.1007/s00726-026-03534-0
PMCID: PMC13534373

Genes

CYP2A6
PIK3CA
TP53
UGT2B7

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 22 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deciphering the molecular heterogeneity of HER2-positive breast cancer: the critical interplay of hormone receptor status and transcriptomic landscapes.PMID 42301336Read ↗

Histopathological and Clinical Features of HER2-Positive Breast Cancers across Hormone Receptor Subgroups: A Cross-Sectional AnalysisSemantic proximity Read ↗

Combined Hormone Receptor and Human Epidermal Growth Factor Receptor-2 Expression Reflects Inter-and Intra-tumor Heterogeneity in Hormone Receptor-positive/human Epidermal Growth Factor Receptor-2-positive Breast CancerSemantic proximity Read ↗

Molecular and Cellular Heterogeneity in Breast CancerSemantic proximity Read ↗

Integrative genomic and transcriptomic analyses illuminate the ontology of HER2-low breast carcinomas.Semantic proximity Read ↗

The therapeutic response of ER+/HER2− breast cancers differs according to the molecular Basal or Luminal subtypeSemantic proximity Read ↗

Dissecting the biological heterogeneity of HER2-positive breast cancerSemantic proximity Read ↗

HER2 in solid tumors: more than 10 years under the microscope; where are we now?Semantic proximity Read ↗

The genomic landscape of HER2 negative metastatic breast cancer with loss of estrogen and progesterone receptors.Semantic proximity Read ↗

Triple positive breast cancer: a distinct subtype?Semantic proximity Read ↗

HER2 is not a cancer subtype but rather a pan-cancer event and is highly enriched in AR-driven breast tumorsSemantic proximity Read ↗

The HER-2 Receptor and Breast Cancer: Ten Years of Targeted Anti–HER-2 Therapy and Personalized MedicineSemantic proximity Read ↗

Deciphering HER2 Breast Cancer Disease: Biological and Clinical ImplicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.